Endocrine System Diseases Clinical Trial
— CALYPSOOfficial title:
A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chronic Hypoparathyroidism (CALYPSO)
Verified date | March 2024 |
Source | Amolyt Pharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is investigating the safety and efficacy of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (cHP). During the first 24 weeks of the trial, participants will be randomized to receive eneboparatide or placebo. Study treatment is blinded: patients and doctors will not know which group each patient has been randomized to. All patients will start with a fixed dose of study treatment (eneboparatide or placebo), administered subcutaneously with a pre-filled pen. Study treatment will be individually titrated. After completion of the first 24 weeks, patients will be treated in the open label extension part of the study for 28 weeks. During this phase, all patients (including patients that were in the placebo group) will receive eneboparatide.
Status | Active, not recruiting |
Enrollment | 165 |
Est. completion date | June 2025 |
Est. primary completion date | November 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Males and Females, 18-80 years of age 2. Patients with cHP for =12 months at the time of screening 3. Two paired measurements of showing low parathyroid hormone (PTH) and serum calcium either below normal or within normal under standard of care 4. Requirement for therapy with calcitriol =0.5 mcg per day or alphacalcidol =1 mcg per day, and requirement for supplemental oral calcium treatment =1000 mg per day over and above patient's dietary calcium intake at Day 1 visit 5. Successful completion of the Optimization period based on two consecutive measurements of albumin-adjusted serum calcium at least 1 week apart within the range of 7.8 to 9.0 mg/dL and with no more than 25% of change in the daily dose of any of active vitamin D and oral calcium supplements between the two measurements 6. Thyroid-stimulating hormone (TSH) within the lower limit of normal and 1.5-fold of the upper limit of normal at screening; if on suppressive therapy for a history of thyroid cancer, TSH level must be =0.2 mIU/mL and thyroid medication should be stable for at least 6 weeks prior to treatment 7. Prior to start of treatment: - Magnesium level within laboratory normal limits - 25(OH) vitamin D levels of 30-70 ng/mL (75-175 nmol/L) 8. eGFR =30 mL/min/1.73m² during screening 9. Able to perform daily subcutaneous self-injections of study drug (or have a designee to perform injections) via a pre-filled injection pen 10. Female patients of non-childbearing potential or using an effective method of contraception throughout the study. Women of childbearing potential should have a negative pregnancy test. 11. Able and willing to provide written and signed informed consent in accordance with GCP Exclusion Criteria: 1. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation 2. Clinically significant abnormal values at screening for hematology, clinical chemistry, coagulation or urinalysis 3. Abnormal arterial pressure at screening, defined as (1) systolic blood pressure <100 mmHg, or (2) systolic blood pressure >150 mmHg, and/or diastolic blood pressure >100 mmHg. 4. Heart rate at rest outside the range of 50-100 beats/minute at screening 5. Clinically significant abnormal standard 12-lead electrocardiogram indicative of severe cardiac disease 6. Known history of autosomal-dominant hypocalcemia or known pseudohypoparathyroidism (impaired responsiveness to PTH) 7. Any current disease (other than hypoparathyroidism) that might affect calcium metabolism, calcium-phosphate homeostasis or PTH levels 8. Patients with increased risk for osteosarcoma 9. Current uncontrolled active disease processes that may adversely affect gastrointestinal absorption 10. History of cerebrovascular accident within 6 months prior to screening 11. History of active uncontrolled malignancy over the past 2 years at time of screening 12. History of any other cancer other than thyroid cancer (except basal cell skin cancer or squamous cell skin cancer) who have not been disease-free for a period of at least 2 years at the time of screening 13. Acute gout <2 months prior to screening 14. Dependent on parenteral calcium infusions to maintain calcium homeostasis 15. Use of medications such as loop and thiazide diuretics, raloxifene hydrochloride, lithium, methotrexate, cardiac glycosides or systemic corticosteroids within 4 weeks prior to start of treatment 16. Previous treatment with PTH/parathyroid hormone-related protein-like drugs, including PTH(1-84) and PTH(1-34) within 3 months of screening 17. Use of other drugs known to influence calcium and bone metabolism within 4 weeks of screening 18. Use of oral bisphosphonates within 6 months of screening or intravenous bisphosphonate within 12 months of screening 19. Use of denosumab within 18 months of screening 20. Seizure disorder/epilepsy with history of a seizure within 6 months of screening 21. History of symptomatic urinary tract calculi within 3 months of screening 22. Irradiation to the skeleton within 2 years of screening 23. Pregnant or breastfeeding female patients 24. Participation in any other interventional study in which the patient received an investigational drug or device within 2 months or within 5 times the half-life of the investigational drug (whichever comes first) prior to screening 25. Any disease or condition that, in the opinion of the investigator, may require treatment or make the subject unlikely to fully complete the trial, or any condition that presents undue risk from the study treatment or procedures, including treated malignancies that are likely to recur within the approximate duration of the trial 26. Any other reason that in the opinion of the investigator would prevent the subject from completing participation or following the trial schedule 27. Known allergy or sensitivity to PTH or any of the excipients |
Country | Name | City | State |
---|---|---|---|
Canada | Bone Research and Education Center | Oakville | Ontario |
Canada | CHU de Quebec Research Centre | Québec | |
Canada | Eastern Regional Health Authority Health Sciences Centre | Saint John's | Newfoundland and Labrador |
Denmark | Aarhaus University Hospital | Aarhus | |
Denmark | Rigshospitalet | Copenhagen | |
France | Hopital de la Conception-APHM | Marseille | |
France | CHU de Nantes - Hôtel-Dieu | Nantes | |
France | Hospital Bicetre AP-HP | Paris | |
Germany | Universitatsklinikum Carl Gustav Carus an der TU Dresden | Dresden | |
Germany | Medicover Neuroendokrinologie MVZ | Munich | |
Germany | Universitaetsklinikum Wuerzburg | Würzburg | |
Hungary | Semmelweis Egyetem Belgyogyaszati es Hematologiai Klinika | Budapest | |
Hungary | Pecsi Tudomanyegyetem | Pécs | |
Italy | Azienda Ospedaliero Universitaria de Bologna, Policlinico Sant Orsola Malpighi | Bologna | |
Italy | Azienda Ospedaliera Universitaria Careggi | Firenze | |
Italy | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano | Milano | |
Italy | Azienda Ospedaliera Universitaria Pisana-Ospedale di Cisanello | Pisa | |
Italy | Via Alvaro del Portillo, 200, Roma, Italy 00128 | Roma | |
Netherlands | Leiden University Medical Center | Leiden | |
Netherlands | Eramus MC - University Medical Center | Rotterdam | |
Poland | Medycyny Nuklearnej i Chorob Wewnetrznych | Kraków | |
Poland | Instytut Centrum Zdrowia Matki Polki. Klinika Endokrynologii Chorob Metabolicznych | Lódz | |
Poland | Cendrum Zdrowi MDM - EB Group Sp. | Warsaw | |
Portugal | Hospital da Luz Lisboa | Lisboa | |
Portugal | Centro Hospital Vila Nova de Faia/Espinho | Porto | |
Spain | Hospital Universitari Vall d'Hebron | Barcelona | |
Spain | Complejo Hospitalario Universitario de A Coruna | Coruña | |
Spain | Clinica Universidad de Navarra | Pamplona | |
Spain | Hospital Universitario Virgen del Rocio | Sevilla | |
United Kingdom | University Hospitals of Leicester NHS Trust | Leicester | |
United Kingdom | Norfolk & Norwich University NHS Foundation Trust, Quadrum Institute | Norwich | |
United Kingdom | Churchill Hospital | Oxford | |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | University of Chicago - Medical Center | Chicago | Illinois |
United States | The Ohio State University Wexner Medical Center | Columbus | Ohio |
United States | Denver Endocrinology Diabetes and Thyroid Center | Denver | Colorado |
United States | Academy of Diabetes, Thyroid and Endocrine | El Paso | Texas |
United States | North Shore University Health System | Evanston | Illinois |
United States | Physician's East Endocrinology | Greenville | North Carolina |
United States | Indiana University (IU) Health University Hospital | Indianapolis | Indiana |
United States | Colombia University Irving Medical Center | New York | New York |
United States | The Children's Hospital of Philadelphia (CHOP) | Philadelphia | Pennsylvania |
United States | The Children's Hospital of Philadephia | Philadelphia | Pennsylvania |
United States | Thomas Jefferson University | Philadelphia | Pennsylvania |
United States | Northern Nevada Endocrinology | Reno | Nevada |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Arthritis Northwest, PLLC | Spokane | Washington |
United States | Harbor UCLA Medical Center Endocrinology | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
Amolyt Pharma |
United States, Canada, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy - Primary Endpoint | After 24 weeks of treatment, the proportion of patients in the eneboparatide treatment group vs. placebo:
Achieving complete independence from active vitamin D; Achieving independence from therapeutic doses of oral calcium (i.e. taking oral elemental calcium supplements =600 mg/day); and With albumin-adjusted serum calcium within the normal range (8.3 to 10.6 mg/dL). |
24 weeks | |
Secondary | Hypercalciuria | Proportion of patients who had hypercalciuria at baseline and normalize 24-hour urinary calcium excretion level (i.e., achieve <250 mg/24 hours for females or <300 mg/24 hours for males) | 24 weeks | |
Secondary | Change from baseline in the HPT-DD-SE - Physical Domain score | Change from baseline in patient's symptoms, as assessed by the average weekly HPT-DD-SE physical domain score in the eneboparatide treatment group vs. placebo | 24 weeks | |
Secondary | Change from baseline in the HPT-DD-SE - Cognitive Domain score | Change from baseline in patient's symptoms, as assessed by the average weekly HPT-DD-SE cognitive domain score in the eneboparatide treatment group vs. placebo | 24 weeks | |
Secondary | Change from baseline in the HPT-LIQ - Physical Functioning Domain score | Change from baseline in the HPT-LIQ Physical Functioning domain score, in the eneboparatide treatment group vs. placebo | 24 weeks | |
Secondary | Change from baseline in the SF-36 Physical Functioning subscore | Change from baseline in the SF-36 Physical Functioning subscore in the eneboparatide treatment group vs. placebo | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A | |
Active, not recruiting |
NCT05505994 -
The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin
|
Phase 3 | |
Completed |
NCT03675360 -
Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial
|
N/A | |
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Terminated |
NCT00935766 -
Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
|
Phase 3 | |
Terminated |
NCT00174187 -
Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy
|
Phase 3 | |
Completed |
NCT03717298 -
Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT05014204 -
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
|
N/A | |
Completed |
NCT03562897 -
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
|
Phase 2 | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05445284 -
Group Education Trial to Improve Transition for Parents of Adolescents With T1D
|
N/A | |
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
Completed |
NCT03725813 -
Study Evaluating the Effect of Person-centred Care for Patients Admitted for Inpatient Care at an Internal Medicine Unit
|
N/A | |
Recruiting |
NCT04556071 -
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT03335254 -
A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
|
Phase 1/Phase 2 | |
Completed |
NCT04488432 -
Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant
|
||
Recruiting |
NCT05084079 -
Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in SIIT
|
Phase 4 | |
Completed |
NCT03305016 -
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
|
Phase 3 |